Skip to main content
SpringerLink
Log in

UK NICE has recommended the use of natalizumab [Tysabri; Biogen, Elan] in patients with highly active, relapsing-remitting multiple sclerosis (MS).

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Biogen Idec, Elan Corporation plc.NICE Recommends TYSABRI (R) for use in Highly Active Relapsing Remitting Multiple Sclerosis. Media Release: 22 Aug 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

UK NICE has recommended the use of natalizumab [Tysabri; Biogen, Elan] in patients with highly active, relapsing-remitting multiple sclerosis (MS).. Pharmacoecon. Outcomes News 536, 2 (2007). https://doi.org/10.2165/00151234-200705360-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705360-00004

Keywords

Search

Navigation